145 related articles for article (PubMed ID: 23515409)
1. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.
Winter MC; Wilson C; Syddall SP; Cross SS; Evans A; Ingram CE; Jolley IJ; Hatton MQ; Freeman JV; Mori S; Holen I; Coleman RE
Clin Cancer Res; 2013 May; 19(10):2755-65. PubMed ID: 23515409
[TBL] [Abstract][Full Text] [Related]
2. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Charehbili A; van de Ven S; Smit VT; Meershoek-Klein Kranenbarg E; Hamdy NA; Putter H; Heijns JB; van Warmerdam LJ; Kessels L; Dercksen M; Pepels MJ; Maartense E; van Laarhoven HW; Vriens B; Wasser MN; van Leeuwen-Stok AE; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR;
Ann Oncol; 2014 May; 25(5):998-1004. PubMed ID: 24585721
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.
Wu W; Chen J; Deng H; Jin L; He Z; Rao N; Nie Y; Yao Y; Yang Y; Su F; Liu J
BMC Cancer; 2021 Jul; 21(1):862. PubMed ID: 34315439
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
Ishikawa T; Akazawa K; Hasegawa Y; Tanino H; Horiguchi J; Miura D; Hayashi M; Kohno N
J Surg Res; 2017 Dec; 220():46-51. PubMed ID: 29180210
[TBL] [Abstract][Full Text] [Related]
7. Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
Hasegawa Y; Tanino H; Horiguchi J; Miura D; Ishikawa T; Hayashi M; Takao S; Kim SJ; Yamagami K; Miyashita M; Konishi M; Shigeoka Y; Suzuki M; Taguchi T; Kubota T; Akazawa K; Kohno N;
PLoS One; 2015; 10(12):e0143643. PubMed ID: 26633806
[TBL] [Abstract][Full Text] [Related]
8. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer.
Alamgeer M; Ganju V; Kumar B; Fox J; Hart S; White M; Harris M; Stuckey J; Prodanovic Z; Schneider-Kolsky ME; Watkins DN
Breast Cancer Res; 2014 Apr; 16(2):R44. PubMed ID: 24762066
[TBL] [Abstract][Full Text] [Related]
9. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
10. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Vogt U; Bielawski KP; Bosse U; Schlotter CM
Oncol Rep; 2004 Nov; 12(5):1109-14. PubMed ID: 15492801
[TBL] [Abstract][Full Text] [Related]
11. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
13. [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Yin HF; Wang YH; Qin XQ; Zhang H; Li T; Ye JM; Liu YH
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):858-62. PubMed ID: 20137353
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
[TBL] [Abstract][Full Text] [Related]
15. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
[TBL] [Abstract][Full Text] [Related]
17. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Lv M; Li B; Li Y; Mao X; Yao F; Jin F
Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
[TBL] [Abstract][Full Text] [Related]
19. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
[TBL] [Abstract][Full Text] [Related]
20. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
